Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?
about
Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer.Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.Cost of noninfectious comorbidities in patients with HIV.Crocetin shifts autophagic cell survival to death of breast cancer cells in chemotherapy.Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?
P2860
Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Adjuvant cyclophosphamide, met ...... cancer--is it cost-effective?
@ast
Adjuvant cyclophosphamide, met ...... cancer--is it cost-effective?
@en
type
label
Adjuvant cyclophosphamide, met ...... cancer--is it cost-effective?
@ast
Adjuvant cyclophosphamide, met ...... cancer--is it cost-effective?
@en
prefLabel
Adjuvant cyclophosphamide, met ...... cancer--is it cost-effective?
@ast
Adjuvant cyclophosphamide, met ...... cancer--is it cost-effective?
@en
P2860
P356
P1433
P1476
Adjuvant cyclophosphamide, met ...... cancer--is it cost-effective?
@en
P2093
P2860
P356
10.1080/028418600430941
P577
2000-01-01T00:00:00Z